The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
BUSINESS
Astellas/Seattle Genetics Nabs FDA OK for 1st-in-Class ADC
Astellas Pharma and Seattle Genetics said on December 18 that they have won the US FDA’s accelerated approval for their antibody-drug conjugate (ADC) Padcev (enfortumab vedotin) for the treatment of certain adult patients with advanced urothelial cancer. The quick green…
To read the full story
Related Article
BUSINESS
- Takeda Aims for Mid-Teens Annual Growth in Japan Oncology Biz: Exec
March 8, 2021
- Viatris Rolls Out 3 Follow-On AGs for Norvasc, Cardenalin, Relpax
March 8, 2021
- Japan Ethical Drug Sales Down 5.3% in January: Crecon
March 8, 2021
- Sumitomo Dainippon Ditches Napabucasin, 27 Billion Yen Impairment Loss to Be Incurred in FY2021
March 8, 2021
- Takeda Submits NDA for Moderna Vaccine in Japan
March 5, 2021
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
By managing personal bias during the interview process, hiring managers can significantly improve their hit rate placing winning candidates. The trouble is, it’s easier said than done. It’s only natural we tend to like people we can relate to, people…